The Effect of Fc gamma RIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study

Buyukkurt N., ÖZCAN M. A., Ergene U., Payzin B., Tunah S., DEMİRKAN F., ...More

TURKISH JOURNAL OF HEMATOLOGY, vol.32, no.2, pp.152-157, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.4274/tjh.2013.0367
  • Journal Name: TURKISH JOURNAL OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.152-157
  • Keywords: Fc gamma RIIIA, Diffuse large B-cell lymphoma, Rituximab, ANTI-CD20 MONOCLONAL-ANTIBODY, RITUXIMAB THERAPY, CHOP, EXPRESSION
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objective: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the Fc gamma RIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we investigated the impact of Fc gamma RIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS).